Tau proteins are microtubule-binding proteins found in neurons of the human brain. They are also known as microtubule-associated proteins (MAPs) and are involved in a variety of cellular functions, including stabilization of microtubule structure, intracellular transport, regulation of gene expression and cargo sorting. They are found in the axon of most post-mitotic cells and their concentration is higher in the axons of neurons than in the rest of the cell. Tau proteins are highly conserved proteins, meaning they are present in all organisms from bacteria to humans. They are made up of both an amino-terminal and a carboxy-terminal region, each with different functions. The amino-terminal region is involved in binding to microtubules and the carboxy-terminal region is responsible for the tau proteins’ interactions with other proteins and molecules. Tau proteins help to stabilize microtubules and enable the cell to transport molecules down the length of the axon. Imbalances in tau protein levels can disrupt this process. In human brains, tau proteins form clusters called neurofibrillary tangles (NFTs). The formation of NFTs occurs during the progression of neurological diseases such as Alzheimer's disease and some forms of dementia, resulting in cell death and damage to the neuronal network. Tau proteins exist in different isoforms or forms, depending on the environment in which they are found. Under normal physiological conditions, the isoforms of tau proteins act as stabilizers of the microtubules and serve an important role in the regulation of intracellular transport. When abnormal conditions arise, such as a decrease in the intracellular supply of energy, the normal tau isoforms are altered and new hyperphosphorylated tau isoforms are generated. These altered isoforms cause the tau protein to become insoluble and lose its ability to bind to microtubules, leading to instability in the cell's structure and impaired function. The study of tau proteins is important in understanding and tackling neurodegenerative diseases like Alzheimer’s and has potential applications in therapies for other conditions. Research into tau protein inhibitors is ongoing, with the aim of finding molecules that can inhibit the accumulation of the toxic tau isoforms and thereby reduce their damaging effects on the neuronal network.
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Modeling early neurologic trajectories after elevated leg positioning (ELP): A secondary analysis of the LEG-UP randomized feasibility study
Kayode Ahmed, The University of Texas MD Anderson Cancer Center, United States
Title : Neuro-exergaming for non-verbal autism spectrum: A case study of neuropsychological function after 15 sessions of pedal-n-play iPACES
Cay Anderson Hanley, iPACES, United States
Title : Prescribing joy: The importance of integrating memory cafes into dementia care
Saul Beaumont, Massachusetts Advisory Council on Alzheimer's Disease and All Other Dementias, United States